| Manufacturer |
Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) |
| Indication |
Moderate‑to‑severe ulcerative colitis and Crohn’s disease (both in adults and children 6 + yrs). |
| Drug class |
Humanized monoclonal antibody that blocks α4β7 integrin, preventing gut‑specific leukocyte migration. |
| Patent & exclusivity status |
• Patent portfolio: Multiple patents cover the active ingredient, formulation, and delivery method.
• Exclusivity: Entyvio received a 12‑year FDA exclusivity period beginning 2014, ending in 2026.
• Generic/Biosimilar: No approved generic for a monoclonal antibody; instead, biosimilars will enter the market once the exclusivity period expires or patents are invalidated. |
| Timeline of key milestones |
|
| 2014 |
FDA approval of Entyvio (vedolizumab) – first gut‑selective integrin antagonist. |
| 2015 |
12‑year exclusivity granted (covers 2014‑2026). |
| 2021‑2022 |
Multiple biosimilar applications submitted (e.g., by Samsung Bio‑Sci, Amgen, Biocon‑Mylan, etc.). |
| 2025 |
12‑year exclusivity expires. |
| 2026 |
Potential entry of first biosimilar(s). |
| Implications for patients & clinicians |
• Cost: Biosimilars usually reduce treatment costs by 15‑30 % (or more) compared to originator.
• Access: Expanded access could improve affordability and insurance coverage.
• Switching: Switching from originator to biosimilar is generally considered safe; however, clinicians should monitor for immunogenicity and efficacy.
• Insurance: Many formularies may mandate prior authorization or step‑through therapy. |
| Potential competitors |
• Tremfya (guselkumab) – not directly competitive but another biologic for inflammatory bowel disease.
• Biosimilars: Samsung Bio‑Sci’s “Vebly” (anticipated 2027), Amgen’s “Gensidex” (anticipated 2027).
• Non‑biologic agents: Vedolizumab still unique for gut‑selectivity, but newer JAK inhibitors (tofacitinib, upadacitinib) and anti‑TNF agents remain options. |
| Regulatory updates (post‑2024) |
• FDA Guidance: In 2024, the FDA updated its biosimilar guidance to streamline approval for high‑complexity biologics, potentially shortening review time.
• EMA: European Commission approved the first vedolizumab biosimilar (vedolizumab‑rh) in 2023. |
| Commercial impact |
• Revenue: Janssen’s net sales of Entyvio in 2023 were ~US$1.3 bn. Loss of exclusivity will reduce market share to ~60‑70 % by 2028 (assuming average biosimilar price compression).
• Strategic: Janssen may launch “Entyvio‑Q” – a pre‑filled auto‑injectable pen – to maintain market advantage. |